Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Current status of therapy with omalizumab in children.
[allergic bronchopulmonary aspergillosis]
There
are
a
considerable
number
of
patients
with
moderate
-
to
-
severe
uncontrolled
asthma
needing
additional
therapy
.
Omalizumab
,
an
anti-
IgE
monoclonal
antibody
,
improves
control
while
reducing
IgE-mediated
airway
inflammation
and
potentially
interfering
in
the
progressive
remodeling
process
.
The
clinical
implications
are
reductions
in
the
required
doses
of
inhaled
steroids
,
a
decrease
in
exacerbation
number
,
and
a
reduction
in
emergency
room
visits
and
hospitalizations
.
In
addition
to
its
use
in
asthma
,
there
is
an
increasing
interest
on
the
use
of
omalizumab
for
other
uncontrolled
IgE-mediated
diseases
,
supported
by
the
favorable
risk-benefit
background
.
The
present
review
explores
the
most
recent
publications
on
the
use
of
omalizumab
for
allergic
asthma
and
other
atopic
conditions
in
children
.
Omalizumab
has
also
shown
efficacy
in
allergic
rhinitis
,
and
it
is
being
investigated
in
the
treatment
of
anaphylaxis
,
food
allergy
,
atopic
dermatitis
,
and
chronic
spontaneous
urticaria
,
as
well
as
cystic
fibrosis
and
allergic
bronchopulmonary
aspergillosis
.
Despite
the
benefits
shown
so
far
,
more
data
are
needed
for
optimal
use
in
these
conditions
,
particularly
looking
at
the
safety
issues
that
have
to
be
confirmed
.
Confirmatory
evidence
on
the
efficacy
and
safety
of
omalizumab
in
children
is
reviewed
,
as
well
as
newest
fields
of
applicability
in
which
IgE
is
involved
in
disease
mechanism
.
Diseases
Validation
Diseases presenting
"hospitalizations"
symptom
allergic bronchopulmonary aspergillosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom
